Vaxart (NASDAQ:VXRT) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.63 and traded as low as $0.31. Vaxart shares last traded at $0.32, with a volume of 1,136,429 shares trading hands.

Analyst Ratings Changes

Separately, B. Riley dropped their price target on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th.

Vaxart Price Performance

The company's 50 day moving average price is $0.45 and its 200 day moving average price is $0.61. The firm has a market capitalization of $91.44 million, a P/E ratio of -0.98 and a beta of 1.57.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The company had revenue of $15.19 million for the quarter, compared to analyst estimates of $15.68 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. On average, research analysts anticipate that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC boosted its position in shares of Vaxart by 95.0% during the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock worth $342,000 after buying an additional 251,789 shares during the period. Graham Capital Management L.P. boosted its position in Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 32,482 shares during the last quarter. Bank of America Corp DE boosted its position in Vaxart by 10.8% during the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 17,942 shares during the last quarter. Silverarc Capital Management LLC boosted its position in Vaxart by 7.8% during the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock valued at $714,000 after purchasing an additional 77,782 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Vaxart during the fourth quarter valued at approximately $129,000. 18.05% of the stock is owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.